Xu X Q, Wang H, Shan S, You H, Nan Y M, Xu X Y, Duan Z P, Wei L, Hou J L, Zhuang H, Jia J D, Kong Y Y
Clinical Epidemiology and EBM Unit, Beijing Friendship Hospital, Capital Medical University, Beijing Clinical Research Institute, Beijing 100050, China.
Beijing Clinical Research Institute, Beijing 100050, China.
Zhonghua Gan Zang Bing Za Zhi. 2023 Jul 20;31(7):698-704. doi: 10.3760/cma.j.cn501113-20230518-00226.
To understand ten-year changes in clinical characteristics and antiviral treatment patterns of chronic hepatitis B in China. Patients with chronic HBV infection:demographic, virologic, hematologic, blood biochemistry, and antiviral treatment data were extracted from the China Registry of Hepatitis B (CR-HepB) database between 2012 and 2022 for descriptive statistics and change trend analysis. Multiple group comparisons were conducted using the Kruskal Wallis H test, while counting data was compared between groups using (2) test. A total of 180 012 patients with chronic HBV infection were included, with a median age of 40 years old, and a male proportion accounting for 60.2%. The HBeAg positive rate was 43.3%. Over time, the median age of new patients each year increased from 39 to 47 years, while the HBeAg positive rate decreased from 51.3% to 32.8%. The initial diagnosis of patients was mainly CHB (71.4%), followed by hepatitis B cirrhosis (11.8%), inactive HBsAg carrier status (10.6%), and chronic HBV carrier status (6.2%). Among the newly registered patients every year from 2012 to 2022, the proportion of hepatitis B cirrhosis remained stable, but after 2019, the proportion of CHB increased and the proportion of other diagnoses decreased. The proportion of patients with cirrhosis increased with age in different age groups, with 3.5%, 19.3%, and 30.4% in the < 40, 40-69, and≥70 age groups, respectively. The proportion of women in patients with cirrhosis also increased with age, from 16.1% in those < 30 years old to 44.3% in those≥80 years old. From 2012 to 2022, the proportion of patients receiving first-line nucleos(t)ide analog antiviral treatment increased year by year, from 51.0% in 2012-2013 to 99.8% in 2022. The CR-HepB registration data reflect the changes in clinical characteristics and antiviral treatment patterns in patients with chronic HBV infection in China over the past ten years and can thus provide a reference to promote hepatitis B diagnosis and treatment practice, as well as scientific research.
了解中国慢性乙型肝炎临床特征及抗病毒治疗模式的十年变化。慢性HBV感染患者：从2012年至2022年的中国乙型肝炎登记数据库（CR-HepB）中提取人口统计学、病毒学、血液学、血液生化及抗病毒治疗数据，进行描述性统计和变化趋势分析。多组比较采用Kruskal Wallis H检验，计数资料组间比较采用χ²检验。共纳入180012例慢性HBV感染患者，中位年龄40岁，男性比例占60.2%。HBeAg阳性率为43.3%。随着时间推移，每年新患者的中位年龄从39岁增至47岁，而HBeAg阳性率从51.3%降至32.8%。患者初始诊断主要为慢性乙型肝炎（CHB，71.4%），其次为乙型肝炎肝硬化（11.8%）、非活动性HBsAg携带者状态（10.6%）和慢性HBV携带者状态（6.2%）。在2012年至2022年每年新登记的患者中，乙型肝炎肝硬化的比例保持稳定，但2019年后，CHB的比例增加，其他诊断的比例下降。不同年龄组中，肝硬化患者的比例随年龄增长而增加，<40岁、40 - 69岁和≥70岁年龄组分别为3.5%、19.3%和30.4%。肝硬化患者中女性比例也随年龄增长而增加，从<30岁患者中的16.1%增至≥80岁患者中的44.3%。2012年至2022年，接受一线核苷（酸）类似物抗病毒治疗的患者比例逐年增加，从2012 - 2013年的51.0%增至2022年的99.8%。CR-HepB登记数据反映了中国慢性HBV感染患者过去十年临床特征及抗病毒治疗模式的变化，可为促进乙型肝炎诊疗实践及科研提供参考。
Zotero 插件